drugset / Trial / NCT00541463

A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)

NCT00541463

Phase 2 Completed 330 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

A study comparing Indinavir plus Ritonavir plus 2 NRTIs vs. Nelfinavir 1250 plus two nucleoside reverse transcriptase inhibitors (NRTIs) in the treatment of HIV positive patients who have not responded to or are intolerant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) containing treatment.

Timeline

Start
2001-01
Primary completion
Completion
2003-05

Drugs

EvaluationDrugModalityDoseRoute
Subject INDINAVIR ANHYDROUS Other / unclassified 800 mg
Subject Nelfinavir Other / unclassified 1250 mg